Alzheimer's | The TYP

Blog Posts

Mar 11, 20224 min read

THE TEN BILLION UNICORN IN INMUNE BIO: THE TESTIMONIALS SO FAR

Introduction Apart from the abundant preclinical data showing efficacy in animals, XPro has been tested in six patients in the Phase 1...

Mar 8, 20226 min read

NFL AS A HIGHLY RELEVANT BIOMARKER IN AD AND OTHER NEUROLOGICAL DISEASES

What is neurofilament-light chain (NfL)? Neurofilaments, the larger group to which NfL belongs, are structural components of neuronal...

Mar 7, 20229 min read

ANNOVIS: BUNTANETAP/ANVS-401/POSIPHEN AND MY THOUGHTS ON THE PREVIOUSLY REJECTED PHENSERINE

A small recap of existing drugs approved for AD There are four FDA-approved drugs for Alzheimer’s disease, three of which are...

Mar 6, 20226 min read

THE CURIOUS CASE OF CORTEXYME AND HOW I RELATE IT TO INMUNE BIO

What most investors seem to forget is diving into scientific literature The trials and tribulations of the stock market seem, to me, in...

Jan 9, 202214 min read

THE TEN BILLION DOLLAR UNICORN IN INMUNE BIO: PARTNERSHIP/BUYOUT AND VALUATION CONSIDERATIONS

My views on possible partnership/buyout and valuation of INMB will be set out below. The highlights are the following. - I consider a...

Dec 17, 202111 min read

THE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART II

Drug XPro of INmune Bio has limitless potential in neurodegenerative diseases such as Alzheimers, ALS, MS, Huntington's, Parkinson's, ...

Dec 14, 202112 min read

THE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART I

Introduction I believe INmune Bio, a company with a market cap of just 200 million dollars at the time of writing, will end up being...

1,055 views3 comments